Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arformoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 5/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 5/20 | 1.00 |
| ▸ | DRD2 | P14416 | 2/20 | 0.87 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.87 |
| ▸ | TSHR | P16473 | 2/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.87 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.87 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.87 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.87 |
| ▸ | DRD3 | P35462 | 1/20 | 0.87 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL17515075 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL29039567 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL4084169 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL31697543 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL29369526 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL82829 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL1650339 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL1660800 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL3040814 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL3670606 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4359402-B1 | IMIDAZOLO INDAZOLE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20260015617-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | NOVARTIS AG (CH) | 2026-01-15 | — | — | US | disclosed |
| US-12398135-B2 | Dimethyl amino azetidine amides as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-26 | — | — | US | disclosed |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-08-12 | — | — | US | disclosed |
| EP-4586263-A2 | SYSTEM AND METHOD FOR CONTROLLING INHALER DOSAGE | ResMed Pty Ltd (AU) | 2025-07-16 | — | — | EP | disclosed |
| EP-3990070-B1 | SYSTEM AND METHOD FOR CONTROLLING INHALER DOSAGE | ResMed Pty Ltd (AU) | 2025-03-19 | — | — | EP | disclosed |
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4114836-B1 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2025-01-08 | — | — | EP | disclosed |
| US-20240363214-A1 | SYSTEMS AND METHODS TO DETERMINE A THERAPY REGIMEN TO TREAT ASTHMA OF A SUBJECT | AsthmaTek, Inc. | 2024-10-31 | — | — | US | disclosed |
| CN-115190878-B | Crystalline hydrates of JAK inhibitor compounds | 施万生物制药研发IP有限责任公司 | 2024-10-29 | — | — | CN | disclosed |
| US-20220306626-A1 | CRYSTALLINE FORM OF A DIHYDROCHLORIDE SALT OF A JAK INHIBITOR COMPOUND | THERAVANCE BIOPHARMA R&D IP, LLC | 2022-09-29 | — | — | US | disclosed |
| US-11453668-B2 | JAK inhibitors containing a 4-membered heterocyclic amide | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-27 | — | — | US | disclosed |
| US-20220289737-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-09-15 | — | — | US | disclosed |
| WO-2022178215-A1 | AMINO AMIDE TETRAHYDRO IMIDAZO PYRIDINES AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| US-20220246260-A1 | SYSTEMS AND METHODS TO DETERMINE A THERAPY REGIMEN TO TREAT ASTHMA OF A SUBJECT | AsthmaTek, Inc. | 2022-08-04 | — | — | US | disclosed |
| WO-2022164616-A1 | SYSTEMS AND METHODS TO DETERMINE A THERAPY REGIMEN TO TREAT ASTHMA OF A SUBJECT | AsthmaTek, Inc. (US) | 2022-08-04 | — | — | WO | disclosed |
| US-20220233093-A1 | SYSTEMS AND METHODS TO PROVIDE A PHYSICIAN INTERFACE THAT ENABLES A PHYSICIAN TO ASSESS ASTHMA OF A SUBJECT AND PROVIDE THERAPEUTIC FEEDBACK | AsthmaTek, Inc. | 2022-07-28 | — | — | US | disclosed |
| WO-2022159288-A1 | SYSTEMS AND METHODS TO PROVIDE A PHYSICIAN INTERFACE THAT ENABLES A PHYSICIAN TO ASSESS ASTHMA OF A SUBJECT AND PROVIDE THERAPEUTIC FEEDBACK | AsthmaTek, Inc. (US) | 2022-07-28 | — | — | WO | disclosed |
| EP-3990070-A1 | SYSTEM AND METHOD FOR CONTROLLING INHALER DOSAGE | ResMed Pty Ltd (AU) | 2022-05-04 | — | — | EP | disclosed |
| CN-114206418-A | System and method for controlling inhaler dose | 瑞思迈私人有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260015617-A1 | DOUBLE STRANDED RNAi AGENTS, COMPOSITIONS AND METHODS OF USE | HMGCR, APOL1, LDLR | ADRB2 2932/4885ADRB1 1901/4885ADRB3 1602/4885 |
| US-20250034131-A1 | DIMETHYL AMINO AZETIDINE AMIDES AS JAK INHIBITORS | JAK1, JAK2, JAK3 | ADRB2 2051/4885ADRB1 2064/4885ADRB3 3069/4885 |
| US-20220289737-A1 | FUSED IMIDAZO-PIPERIDINE JAK INHIBITORS | JAK2, JAK1, JAK3 | ADRB2 3614/4885ADRB1 3149/4885ADRB3 3093/4885 |
| US-12398135-B2 | Dimethyl amino azetidine amides as JAK inhibitors | JAK1, JAK2, JAK3 | ADRB2 2051/4885ADRB1 2064/4885ADRB3 3069/4885 |
| US-11453668-B2 | JAK inhibitors containing a 4-membered heterocyclic amide | JAK1, JAK2, JAK3 | ADRB2 4079/4885ADRB1 3743/4885ADRB3 3977/4885 |
| US-12384761-B2 | Imidazolo indazole compounds as JAK inhibitors | JAK1, JAK3, JAK2 | ADRB2 1575/4885ADRB1 1307/4885ADRB3 1223/4885 |
| US-20220306626-A1 | CRYSTALLINE FORM OF A DIHYDROCHLORIDE SALT OF A JAK INHIBITOR COMPOUND | JAK1, JAK2, JAK3 | ADRB2 4528/4885ADRB1 4493/4885ADRB3 4308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.